ENFLONSIA is a long-acting, preventive monoclonal antibody developed to protect infants against a broad range of respiratory syncytial virus (RSV) disease severity. This includes severe cases that may lead to hospitalization. It is the first and only RSV preventive option that offers a weight-independent, single-dose administration, simplifying protection across all infants regardless of size or gestational age. ENFLONSIA provides consistent, season-long immunity with a convenient, once-per-season approach.